目的 觀察腦心通膠囊聯(lián)合卡維地洛治療原發(fā)性高血壓的臨床療效。方法 選取2016年1月-2017年1月北京恒和中西醫(yī)結(jié)合醫(yī)院收治初診的120例原發(fā)性高血壓患者，隨機(jī)分為對(duì)照組和治療組，每組各60例。對(duì)照組患者口服卡維地洛膠囊，1粒/次，第1周1次/d，第2周增至2次/d，之后酌情增減用量，原則上不超過4次/d。治療組在對(duì)照組治療基礎(chǔ)上口服腦心通膠囊，2粒/次，3次/d。兩組患者均連續(xù)治療1個(gè)月。觀察兩組的臨床療效，比較兩組治療前后收縮壓、舒張壓、SAS評(píng)分、SDS評(píng)分、生活自理能力評(píng)分的變化情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為73.33%、91.67%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者收縮壓、舒張壓、SAS評(píng)分、SDS評(píng)分均較治療前顯著降低，生活自理能力評(píng)分顯著升高，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組收縮壓、舒張壓、SAS評(píng)分、SDS評(píng)分低于對(duì)照組，生活自理能力評(píng)分高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 腦心通膠囊聯(lián)合卡維地洛治療原發(fā)性高血壓具有明顯的臨床療效，可顯著降低患者收縮壓和舒張壓，提高患者生活自理能力評(píng)分，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the curative effect of Naoxintong capsules combined with carvedilol in treatment of primary hypertension. Methods Patients (120 cases) with primary hypertension in Beijing Henghe Hospital of Integrated Traditional Chinese and Western Medicine from January 2016 to January 2017 were randomly divided into control (60 cases) and treatment (60 cases) groups. Patients in the control group were po administered with Carvedilol Capsules, 1 grain/time, once daily on the first week, twice daily on the second week. After that, the dosage should be increased as appropriate, but the dosage was no more than 4 times/d in principle. Patients in the treatment group were po administered with Naoxintong Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, and the changes of systolic pressure, diastolic blood pressure, SAS score, SDS score, and life self-evaluation ability score in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 73.33% and 91.67%, respectively, and there was difference between two groups (P<0.05). After treatment, systolic pressure, diastolic blood pressure, SAS score, and SDS score in two groups significantly decreased, but life self-evaluation ability score obviously increased, and the difference was statistically significant in the same group (P<0.05). After treatment, systolic pressure, diastolic blood pressure, SAS score, and SDS score in treatment group were lower than those in the control group, but life self-evaluation ability score was higher than that in the control group, and there was difference between two groups (P<0.05). Conclusion Naoxintong Capsules combined with carvedilol has good clinical effect in treatment of primary hypertension, can significantly reduce systolic pressure and diastolic pressure in patients, and can improve life self-evaluation ability score, which has a certain clinical application value.